New therapeutic targets in stroke prevention: the effects of allopurinol on the cerebrovasculature of patients with subcortical stroke

ISRCTN ISRCTN06452574
DOI https://doi.org/10.1186/ISRCTN06452574
Secondary identifying numbers N/A
Submission date
09/09/2005
Registration date
22/11/2005
Last edited
01/02/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Matthew Walters
Scientific

Department of Medicine & Therapeutics
Western Infirmary
44 Church Street
Glasgow
G11 6NT
United Kingdom

Phone +44 (0)141 211 2821
Email gcl203@clinmed.gla.ac.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study objectivesTreatment with xanthine oxydase inhibitor allopurinol will improve cerebrovascular reactivity in patients with subcortical stroke.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedSubcortical stroke.
Intervention3 month allopurinol treatment (300 mg) versus lactose tablet.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Allopurinol
Primary outcome measureThe change in flow velocity in the middle cerebral artery (MCA) following acetazolomide infusion.
Secondary outcome measures1. Change in serum urate
2. Recurrent stroke or other cardiac event
Overall study start date01/11/2005
Completion date01/11/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants80
Key inclusion criteria1. Subcortical stroke
2. Index stroke within 2 weeks and 3 months prior to randomisation
Key exclusion criteria1. >70% Internal carotid artery stenosis
2. Coronary artery disease
3. Other significant comorbidity
4. Contraindication to allopurinol
5. Contraindication to acetazolamide
6. Concurrent azathioprine or 6-mercaptopurine therapy
7. Serum creatinine >250 µmol/l
8. Woman of childbearing potential
Date of first enrolment01/11/2005
Date of final enrolment01/11/2007

Locations

Countries of recruitment

  • Scotland
  • United Kingdom

Study participating centre

Department of Medicine & Therapeutics
Glasgow
G11 6NT
United Kingdom

Sponsor information

Greater Glasgow NHS Board/Glasgow University (UK)
Hospital/treatment centre

c/o Judith Godden
Administration Building
Western Infirmary
Dumbarton Road
Glasgow
G11 6NT
Scotland
United Kingdom

Phone +44 (0)141 211 2000
Email judith.godden@Northglasgow.NHS.Scot.UK
ROR logo "ROR" https://ror.org/05kdz4d87

Funders

Funder type

Charity

West Endowment Fund (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/11/2009 Yes No